Mark Nachtigal, PhDUniversity of Manitoba Autocrine bone morphogenic protein (BMP) inhibition: a novel therapeutic strategy for ovarian cancer? Protein growth factors belonging to the transforming growth factor beta (TGFβ) superfamily, which include bone morphogenic proteins (BMPs), influence the growth, motility, and invasive potential of ovarian cancer cells. Blocking of these pathways may produce a more […]
Read More
Ilona Kryczek, PhDUniversity of Michigan IL-17+ T cells in patients with ovarian cancer T helper cells (Th), a sub-group of white blood cells, play a crucial role in inflammatory responses and autoimmune diseases, but are poorly understood in human pathology. By using our well-established human ovarian cancer model, we propose to map out the basic […]
Read More
Ingegerd Hellstrom, MD, PhDUniversity of Washington Silencing TGFbeta to increase the immunogenicity of ovarian carcinoma cells This study aims to improve a woman’s prognosis by adding a therapeutic vaccination to encourage the body to mount an anti-tumor response using the secreted growth regulatory protein TGFβ (transforming growth factor). Dr. Hellstrom has shown that a mouse […]
Read More
Mark Gavin, MD, PhDUniversity of Minnesota A genetic screen for epithelial ovarian cancer genes With over 80 genes and 200 transcripts implicated in the development of ovarian cancer, there are little similarities among ovarian cancer. It is the goal of this study to identify those genes that are singularly critical to the genesis of the […]
Read More
Faris Farassati, PhD, PharmDUniversity of Minnesota A Novel Strategy for Targeting Ovarian Cancer Mesothelin is a plasma membrane antigen expressed in significantly high levels in mesothelioma and ovarian cancer patients. This study will test the hypothesis that ovarian cancer cells are biologically dependent on the expression of mesothelin for their survival. The results will provide […]
Read More
Heike Daldrup-Link, MD, PhDUniversity of California, San Francisco MR imaging of ovarian cancer with folate-receptor targeted contrast agents Folate-receptors are relatively absent in normal tissues but overexpressed on cancer cells. Therefore, folate-receptor targeted contrast agents have the potential to provide cancer specific imaging. By targeting these receptors so they will appear vividly in magnetic resonance […]
Read More
Dusica Cvetkovic, MDFox Chase Cancer Center Validation of an ovarian cancer biomarker panel in high-risk women This study will examine ovaries removed during prophylactic (preventative) surgery, before ovarian cancer is discovered or suspected. The hypothesis is that aberrant DNA methylation can be detected in the blood of women prior to the onset of clinical symptoms. […]
Read More
Henning Boldt, PhDMayo Clinic The role of pregnancy-associated plasma protein-A (PAPP-A) in ovarian cancer PAPP-A is a protein that has been shown to reduce tumor incidence and burden. Using a PAPP-A mouse model, Dr. Boldt will examine the development of growth of ovarian cancer and the immune response. The results will provide insight into the […]
Read More